ACOD1 Gene Expression as Sepsis Mortality Predictor
Summary
NIH has registered a new observational clinical study (NCT07533994) on ClinicalTrials.gov evaluating ACOD1 gene expression in peripheral blood mononuclear cells as a prognostic biomarker for predicting sepsis mortality. The single-center study will enroll septic ICU patients and correlate ACOD1 expression with clinical severity scores and in-hospital mortality outcomes.
What changed
NIH has registered a new prospective, single-center, observational study on ClinicalTrials.gov titled 'ACOD1 as a Prognostic Marker for Sepsis.' The study will evaluate ACOD1 gene expression measured by RT-qPCR in peripheral blood mononuclear cells within 24-48 hours of ICU admission for predicting sepsis mortality, correlating findings with SOFA, APACHE II, CRP, lactate, and other clinical markers.
This registry entry does not create compliance obligations for external parties. Clinical investigators, research hospitals, and academic medical centers conducting similar biomarker or sepsis research may reference this study for context on emerging prognostic marker evaluation methodologies. The study is registered under GxP-compliant ClinicalTrials.gov procedures.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ACOD1 as a Prognostic Marker for Sepsis
Observational NCT07533994 Kind: OBSERVATIONAL Apr 16, 2026
Abstract
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, with high morbidity and mortality worldwide. Reliable biomarkers are needed for early risk stratification and outcome prediction. This prospective, single-center, observational study aims to evaluate the prognostic value of Acod1 gene expression in peripheral blood mononuclear cells (PBMCs) from septic patients. The primary objective is to assess the sensitivity and specificity of ACOD1 expression measured by RT-qPCR within 24-48 hours of ICU admission for predicting sepsis mortality. Secondary objectives include correlating ACOD1 expression with the SOFA score, and comparing its predictive performance against established clinical markers and scores such as APACHE II, SOFA, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), arterial lactate, and IL-1β expression. The study will also report in-hospital mortality. Findings may support ACOD1 as a novel molecular biomarker for early prognostic assessment in sepsis.
Conditions: Sepsis
Interventions: Blood draw for lab testing.
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.